CellinCells
Latest round
- Series B
Last raised
- Jul 2021
Total raised
- $14M
Investors
- 7
About CellinCells
Based in Seoul, South Korea, and founded in 2014, CellinCells develops regenerative therapies by devising the self-structuring ability of cells as a platform technology. The company saw the potential for use of regenerative therapy while researching the self-structuring ability of cells. CellinCells focused on the development of skin regeneration treatments through 3D tissue shape platform technology. In 2016, the company obtained a patent for a structure for tissue regeneration and manufacturing method. In 2018, CellinCells signed a Research Consignment Contract with Seoul National University Industry-Academic Cooperation Foundation (Seoul National University Hospital Orthopedic Surgery). The company is focused on research and development for its regenerative medicine stem cell therapy technology. CellinCells plans to conduct clinical trials in cooperation with Samsung Seoul Hospital and others.
Who invested in CellinCells
7 investors across 2 rounds
See all investors in CellinCells
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about CellinCells
Who invested in CellinCells?
CellinCells has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CellinCells raised?
CellinCells has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did CellinCells last raise money?
CellinCells's most recent round on record is a Series B, in Jul 2021.
What does CellinCells do?
Based in Seoul, South Korea, and founded in 2014, CellinCells develops regenerative therapies by devising the self-structuring ability of cells as a platform technology.
Where is CellinCells headquartered?
CellinCells is headquartered in Seoul, South Korea.
Which VCs invest in companies like CellinCells?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at CellinCells's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like CellinCells? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.